This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Anti-CD30, iratumumab
Description: MDX-060 is a fully human antibodythat targets CD30, which is a marker for activated lymphocytes and is presenton the malignant cells of Hodgkin's Disease and anaplastic large cell lymphoma. Through its ability to target CD30 expressing tumor cells, MDX-060 mayfacilitate the elimination of such cells by the human immune system.
Deal Structure: MDX-060 was originally developed by Medarex.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The acquisition was completed in September 2009.
Pink Sheet Weekly Trademark Review January 1, 2013
Additional information available to subscribers only: